Frontotemporal Dementia is a term used to describe a group of neurocognitive disorders that encompass progressive dysfunction in executive functioning, behavior, and language. As a group, these disorders typically have brain atrophy in the frontal and/or temporal lobes. Frontotemporal Dementia is considered young-onset dementia, occurring between the ages of 45–65, and is the most common dementia in those under the age of 60.
Frontotemporal Dementia Epidemiology Segmentation
- Total Diagnosed Prevalent Cases of Frontotemporal Dementia
- Prevalent cases of Frontotemporal Dementia by Type
- Subtype-specific Cases of Primary Progressive Aphasia
- Mutation-associated Cases of Frontotemporal Dementia
Frontotemporal Dementia Epidemiological Insights Observed in 2020
- The total prevalent population of Frontotemporal Dementia in the 7MM was estimated to be around 50K cases in 2020.
- Among the 7MM, the total prevalent cases of FTD was the highest in the US with around 28K cases in 2020. Whereas among the EU5, Spain had lowest FTD prevalent cases ( approx 2.5K cases). In addition, Japan had around 5K prevalent FTD cases in 2020.
- Among the suntype-specific prevalent cases of FTD, the US had the highest number of logopenic aphasia cases (approx 2.9K cases) followed by Japan (537 cases) and Spain (33 cases) in 2020.
The Frontotemporal Dementia market size was found to be USD 133.8 million in the 7MM in 2020.
Frontotemporal Dementia Market Drivers
- Development of disease-modifying treatments
- Increase in research initiatives
- New FTD Models and iPSC-derived research tools
Frontotemporal Dementia Market Barriers
- Research associated funding
- Challenges in drug development
- Need for biomarkers
- Trial associated shortcomings
Frontotemporal Dementia Emerging Drugs
The emerging drugs in the Frontotemporal Dementia market are
- AADvac1, and several others
Key Frontotemporal Dementia Companies
The key companies working in the Frontotemporal Dementia market are
- TauRX Pharmaceuticals
- Axon Neuroscience, and several others